CIBC Bancorp USA Inc. Takes $7.40 Million Position in Becton, Dickinson and Company $BDX

CIBC Bancorp USA Inc. purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 39,544 shares of the medical instruments supplier’s stock, valued at approximately $7,401,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Vanguard Group Inc. lifted its position in Becton, Dickinson and Company by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock valued at $6,074,750,000 after purchasing an additional 147,041 shares during the period. State Street Corp grew its position in shares of Becton, Dickinson and Company by 3.4% during the 3rd quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier’s stock worth $2,596,496,000 after buying an additional 459,219 shares during the period. First Eagle Investment Management LLC raised its stake in shares of Becton, Dickinson and Company by 13.8% during the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock worth $1,870,653,000 after buying an additional 1,208,218 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Becton, Dickinson and Company by 7.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock valued at $1,712,715,000 after buying an additional 636,138 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after acquiring an additional 5,174,944 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Down 1.4%

Shares of NYSE:BDX opened at $154.35 on Friday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a market capitalization of $43.95 billion, a PE ratio of 25.18, a price-to-earnings-growth ratio of 11.35 and a beta of 0.24. The business has a fifty day moving average price of $185.53 and a two-hundred day moving average price of $188.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase program on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 953 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 2,787 shares of company stock valued at $551,391 over the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of a number of analyst reports. Piper Sandler reaffirmed a “neutral” rating and set a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Wells Fargo & Company cut their price target on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 10th. Citigroup decreased their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Jefferies Financial Group dropped their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. cut their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.